Drug treatment of heart failure with reduced ejection fraction: defining the role of vericiguat

AJS Coats, H Tolppanen - Drugs, 2021 - Springer
Vericiguat, a novel stimulator of soluble guanylate cyclase (sGC), has shown promising
results in patients with heart failure and reduced ejection fraction (HFrEF) in the recent …

[HTML][HTML] Targeted delivery of soluble guanylate cyclase (sGC) activator cinaciguat to renal mesangial cells via virus-mimetic nanoparticles potentiates anti-fibrotic …

D Fleischmann, M Harloff… - International journal of …, 2021 - mdpi.com
Diabetic nephropathy (DN) ranks among the most detrimental long-term effects of diabetes,
affecting more than 30% of all patients. Within the diseased kidney, intraglomerular …

[HTML][HTML] Contemporary pillars of heart failure with reduced ejection fraction medical therapy

E Rahamim, D Nachman, O Yagel, M Yarkoni… - Journal of Clinical …, 2021 - mdpi.com
Heart failure with reduced ejection fraction (HFrEF) is a clinical condition associated with
cardiac contractility impairment. HFrEF is a significant public health issue with a high …

Cardiovascular therapeutic potential of the redox siblings, nitric oxide (NO•) and Nitroxyl (HNO), in the setting of reactive oxygen species dysregulation

BK Kemp-Harper, A Velagic, N Paolocci… - Reactive Oxygen …, 2021 - Springer
Reactive oxygen species (ROS) dysregulation is a hallmark of cardiovascular disease,
characterised by an imbalance in the synthesis and removal of ROS. ROS such as …

Tracing the path of inhaled nitric oxide: biological consequences of protein nitrosylation

V Bhatia, L Elnagary, S Dakshinamurti - Pediatric pulmonology, 2021 - Wiley Online Library
Nitric oxide (NO) is a comprehensive regulator of vascular and airway tone. Endogenous NO
produced by nitric oxide synthases regulates multiple signaling cascades, including …

Higher susceptibility to heme oxidation and lower protein stability of the rare α1C517Yβ1 sGC variant associated with moyamoya syndrome

I Sharina, K Lezgyieva, Y Krutsenko, E Martin - Biochemical pharmacology, 2021 - Elsevier
NO sensitive soluble guanylyl cyclase (sGC) plays a key role in mediating physiological
functions of NO. Genetic alterations of the GUCY1A3 gene, coding for the α1 subunit of sGC …

[PDF][PDF] 鸟苷酸环化酶刺激剂联合RAS 阻滞剂开启心力衰竭治疗新途径

廖梦阳, 袁璟, 廖玉华 - 临床心血管病杂志, 2021 - lcxxgen.whuhzzs.com
鸟苷酸环化酶刺激剂联合RAS阻滞剂开启心力衰竭治疗新途径 Page 1 2021,37 临床心血管病
杂志 (8):687-691 JournalofClinicalCardiology(China) ·专家论坛· 鸟苷酸环化酶刺激剂联合 …

Gemfibrozil derivatives as activators of soluble guanylyl cyclase–A structure-activity study

KM Gayler, JM Quintana, J Mattke, MA Plunk… - European journal of …, 2021 - Elsevier
Previous studies demonstrated that anti-hyperlipidemic drug gemfibrozil acts as NO-and
heme-independent activator of NO receptor soluble guanylyl cyclase. A series of new …

[HTML][HTML] Inflammation in the Human Periodontium Induces Downregulation of the α1- and β1-Subunits of the sGC in Cementoclasts

Y Korkmaz, B Puladi, K Galler, PW Kämmerer… - International Journal of …, 2021 - mdpi.com
Nitric oxide (NO) binds to soluble guanylyl cyclase (sGC), activates it in a reduced oxidized
heme iron state, and generates cyclic Guanosine Monophosphate (cGMP), which results in …

Role of soluble guanylyl cyclase in renal afferent and efferent arterioles

IC Wennysia, L Zhao, T Schomber… - American Journal …, 2021 - journals.physiology.org
Renal arteriolar tone depends considerably on the dilatory action of nitric oxide (NO) via
activation of soluble guanylyl cyclase (sGC) and cGMP action. NO deficiency and …